Adaptive Design in Early Immuno‑Oncology Trials
Adaptive Design in Early Immuno‑Oncology Trials How to Design Adaptive Early‑Phase Trials in Immuno‑Oncology Why Adaptive Designs Fit Immuno‑Oncology (IO) Phase I/II Early‑phase immuno‑oncology (IO) trials face challenges that traditional cytotoxic programs don’t: delayed and atypical responses, non‑monotonic dose–toxicity and dose–efficacy relationships, and immune‑related adverse events (irAEs) that may emerge outside the classic 28‑day Dose‑Limiting…
Read More “Adaptive Design in Early Immuno‑Oncology Trials” »